The International Pharmacopoeia (Ph. Int.)
In the beginning, it encompassed all the medicines that were available and sold globally. Since 1975 The International Pharmacopoeia focuses on the WHO Model List of Essential Medicines, and more recently on priority medicines of major public health importance and those recommended by specific WHO disease programmes, for instance, medicines to treat malaria, tuberculosis and HIV/AIDS, as well as medicines for children. Priority is also given to medicines evaluated by the Medicines Prequalification Programme.
The work on The International Pharmacopoeia is carried out in collaboration with members of the WHO Expert Advisory Panel on The International Pharmacopoeia and WHO Expert Committee on Specification for Pharmaceutical Preparations and with other specialists. The process involves consultation of and input from WHO Member States’ drug regulatory authorities and national drug quality control laboratories, WHO collaborating Centres, standard-setting organizations and with manufacturers around the world.
Trade names of stationary phases found suitable in performing chromatographic tests described in The International Pharmacopoeia.
Updating mechanism for the section on radiopharmaceuticals in The International Pharmacopoeia
- WHO Expert Committee on Specifications for Pharmaceutical Preparations
The International Pharmacopoeia: revised concepts and future perspectives
Procedure for the development of monographs and other texts for The International Pharmacopoeia
- Current projects: Monographs and general tests under review/revision for inclusion in the International Pharmacopoeia